These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 29460922)

  • 41. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 42. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
    Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
    Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G; Leach BI; Lam L; Tagawa ST
    Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Qingdai Decoction suppresses prostate cancer growth in lethal-stage prostate cancer models.
    Chen Y; Zhou Q; Zhang H; Xu L; Lu L; Shu B; Zhou L; Yuan F
    J Ethnopharmacol; 2023 May; 308():116333. PubMed ID: 36863640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
    Schiewer MJ; Knudsen KE
    Urol Clin North Am; 2021 Aug; 48(3):339-347. PubMed ID: 34210489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 48. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
    Guo C; Sharp A; Gurel B; Crespo M; Figueiredo I; Jain S; Vogl U; Rekowski J; Rouhifard M; Gallagher L; Yuan W; Carreira S; Chandran K; Paschalis A; Colombo I; Stathis A; Bertan C; Seed G; Goodall J; Raynaud F; Ruddle R; Swales KE; Malia J; Bogdan D; Tiu C; Caldwell R; Aversa C; Ferreira A; Neeb A; Tunariu N; Westaby D; Carmichael J; Fenor de la Maza MD; Yap C; Matthews R; Badham H; Prout T; Turner A; Parmar M; Tovey H; Riisnaes R; Flohr P; Gil J; Waugh D; Decordova S; Schlag A; Calì B; Alimonti A; de Bono JS
    Nature; 2023 Nov; 623(7989):1053-1061. PubMed ID: 37844613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W; Ryan CJ
    Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
    Lamb AD; Massie CE; Neal DE
    BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
    Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
    Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnosis and management of neuroendocrine prostate cancer.
    de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
    Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer.
    Kyprianou N; Lucien F
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.
    Kumari S; Sharma V; Tiwari R; Maurya JP; Subudhi BB; Senapati D
    Eur J Pharmacol; 2022 Mar; 919():174807. PubMed ID: 35151649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
    Blas L; Shiota M
    Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.